Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.
An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients.
Kaufman, Matthew
Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer.
See All 17 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer.
Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. Front Oncol. 2021; 11:621088.
View in:
PubMed
authors with profiles
Ravi Salgia